Cervical Cancer Screening and Human Papillomavirus Vaccination among Korean Sexual Minority Women by Sex of Their Sexual Partners

Int J Environ Res Public Health. 2020 Nov 30;17(23):8924. doi: 10.3390/ijerph17238924.

Abstract

Cervical cancer-preventive behaviors in Korean sexual minority women (SMW) are underexplored. We aimed to assess the differences in cervical cancer screening uptake and completion of human papillomavirus (HPV) vaccination among Korean SMW by sex of their sexual partners. This cross-sectional study used data from the 2017 Korean Sexual Minority Women's Health Study; we included Korean lesbian and bisexual women aged ≥20 years. They were divided into three groups: SMW with more than one male sexual partner (male only/both), SMW with only female sexual partners (female-only), or no sexual partner (no partner). Among the 671 participants, 266 (39.6%), 294 (43.8%), and 111 (16.5%) belonged to the male-only/both, female-only, and no partner groups, respectively. Compared to the male-only/both group, the female-only group was significantly less likely to have undergone cervical cancer screening (Adjusted odds ratio (AOR) = 0.24, 95% confidence interval (CI) = 0.15-0.37) and to have completed HPV vaccinations (AOR = 0.58, 95% CI = 0.37-0.91). In conclusion, Korean SMW with only female sexual partners had lower cervical cancer screening and HPV vaccination completion rates than SMW who had male sexual partners. More extensive efforts are needed to improve cervical cancer-preventive behaviors among Korean SMW.

Keywords: South Korea; cancer prevention; cervical cancer; sexual minority women.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alphapapillomavirus*
  • Cross-Sectional Studies
  • Early Detection of Cancer
  • Female
  • Humans
  • Male
  • Papillomavirus Infections* / prevention & control
  • Papillomavirus Vaccines*
  • Republic of Korea
  • Sexual Partners
  • Sexual and Gender Minorities*
  • Uterine Cervical Neoplasms* / prevention & control
  • Vaccination

Substances

  • Papillomavirus Vaccines